Biomarker
dapat memprediksi kekambuhan kanker endometrium
Date:
May 18, 2016
Source:
University of Minnesota Academic Health Center
Summary:
penelitian baru menunjukkan., Enzim deubiquitinating USP14 sebagai biomarker menjanjikan untuk mengidentifikasi risiko kekambuhan pada pasien kanker endometrium.
penelitian baru menunjukkan., Enzim deubiquitinating USP14 sebagai biomarker menjanjikan untuk mengidentifikasi risiko kekambuhan pada pasien kanker endometrium.
.........................
kanker endometrium adalah kanker ginekologi yang paling umum dalam kasus-kasus di AS .
Kebanyakan didiagnosis pada tahap awal dan memiliki prognosis yang baik. Sayangnya,
beberapa pasien dengan stadium awal dan pengalaman kekambuhan kanker endometrium
kelas rendah - dan alasan yang tidak sepenuhnya jelas. Ketika kambuh terjadi, kanker ini
sering resisten terhadap kemoterapi dan memiliki tingkat kematian yang tinggi.
Penelitian baru dari the lab of Martina Bazzaro, Ph.D., of the Masonic Cancer Center,
University of Minnesota and Department of Obstetrics, Gynecology, and Women's Health,
menunjukkan enzim deubiquitinating (DUB) USP14 sebagai biomarker menjanjikan untuk
mengidentifikasi risiko kekambuhan pada pasien kanker endometrium. Dubs telah dikaitkan
dengan perkembangan kanker, inisiasi dan perlawanan dari kemoterapi. Dengan demikian,
penghambatan Dubs tertentu telah diusulkan sebagai terapi yang ditargetkan untuk kanker.
Namun ini adalah pertama kalinya di mana Dubs digunakan sebagai biomarker kanker.
...........................
............................
SILAHKAN MENGGUNAKAN
" MESIN TRANSLATE "..GOOGLE TRANSLATE
DISAMPING KANAN INI.............
PLEASE USE ........ "TRANSLATE MACHINE" .. GOOGLE TRANSLATE BESIDE RIGHT THIS
.................
........................................
........................................
........................................
........................................
T-REC -TUGUMUDA REPTILES COMMUNITY-INDONESIA
More info :
www.trecsemarang2011.blogspot.com
minat gabung : ( menerima keanggotaan seluruh kota dan daerah di Indonesia )
08995557626
DISAMPING KANAN INI.............
PLEASE USE ........ "TRANSLATE MACHINE" .. GOOGLE TRANSLATE BESIDE RIGHT THIS
.................
........................................
........................................
........................................
........................................
T-REC -TUGUMUDA REPTILES COMMUNITY-INDONESIA
More info :
www.trecsemarang2011.blogspot.com
minat gabung : ( menerima keanggotaan seluruh kota dan daerah di Indonesia )
08995557626
FAST RESPON :
08995557626/764047D2
FAST RESPON :
08995557626/764047D2
FAST RESPON :
08995557626/764047D2
FAST RESPON :
08995557626/764047D2
FAST RESPON :
08995557626/764047D2
..................................
..................................
..................................
KSE – KOMUNITAS SATWA EKSOTIK –
EXOTIC PETS
COMMUNITY-- INDONESIA
Visit Our Community and Joint W/ Us....Welcome All Over The World
www.facebook.com/groups/komunitassatwaeksotik/
KSE = KOMUNITAS SATWA EKSOTIK
MENGATASI KENDALA MINAT DAN JARAK
KAMI ADA DI TIAP KOTA DI INDONESIA
DETAIL TENTANG KSE-----KLIK : www.komunitassatwaeksotik-pendaftaran.blogspot.com
GABUNG......... ( menerima keanggotaan seluruh kota dan daerah di Indonesia )
HUBUNGI : 08995557626
Visit Our Community and Joint W/ Us....Welcome All Over The World
www.facebook.com/groups/komunitassatwaeksotik/
KSE = KOMUNITAS SATWA EKSOTIK
MENGATASI KENDALA MINAT DAN JARAK
KAMI ADA DI TIAP KOTA DI INDONESIA
DETAIL TENTANG KSE-----KLIK : www.komunitassatwaeksotik-pendaftaran.blogspot.com
GABUNG......... ( menerima keanggotaan seluruh kota dan daerah di Indonesia )
HUBUNGI : 08995557626
FAST RESPON :
08995557626/764047D2
FAST RESPON :
08995557626/764047D2
FAST RESPON :
08995557626/764047D2
FAST RESPON :
08995557626/764047D2
FAST RESPON :
08995557626/764047D2
........Komunitas T-REC semarang,komunitas
reptil tugumuda reptiles community semarang,komunitas reptil tugumuda
semarang,komunitas semarang,komunitas reptil semarang.............kenali dan
dalami satwa dan reptil dengan bergabung
bersama kami,hubungi 08995557626 / 764047D2.....
........Komunitas KSE ,komunitas satwa eksotik
,komunitas satwa.............kenali dan dalami satwa dan reptil dengan bergabung bersama kami,hubungi
08995557626 / 764047D2.....
.............................
Biomarker may predict
endometrial cancer recurrences
Date:
May 18, 2016
Source:
University of Minnesota Academic Health Center
Summary:
The deubiquitinating
enzyme USP14 as a promising biomarker for identifying risk of recurrence in
endometrial cancer patients, new research suggests.
.........................
Endometrial cancer is the most common gynecologic cancer in the U.S. Most
cases are diagnosed at early stage and have good prognosis. Unfortunately, some
patients with early stage and low grade endometrial cancer experience
recurrence -- and the reasons are not entirely clear. When recurrence happens,
the cancer is often resistant to chemotherapy and has a high rate of mortality.
New research from the
lab of Martina Bazzaro, Ph.D., of the Masonic Cancer Center, University of
Minnesota and Department of Obstetrics, Gynecology, and Women's Health,
suggests the deubiquitinating enzyme (DUB) USP14 as a promising biomarker for
identifying risk of recurrence in endometrial cancer patients. DUBs have been
linked to cancer progression, initiation and the resistance of chemotherapy.
Thus, the inhibition of certain DUBs have been proposed as a targeted therapy
for cancer. However this is the first time where DUBs are used as a cancer
biomarker.
"We have
discovered that women with high levels of USP14 are seven time more likely to
recur than women with low levels of it," says Bazzaro, a medicinal chemist
and cancer biologist who leads this investigation and holds a patent for this
biomarker. She adds that: "knowing a patient's status with regards to
USP14 positivity could make a tremendous difference in terms of how a patients
is treated and ultimately save her life."
Bazzaro is currently
leading an international effort to validate the findings is a larger cohort of
low risk endometrial cancer patients. "Our next step is a clinical trial.
Patients with low risk endometrial cancer will be given the diagnostic exam,
utilizing USP14 to gauge the levels of the cancer," said Bazzaro.
"Those with high amounts -- a positive test -- will be treated more
aggressively than current treatments to help prevent potential recurrence.
Knowing more about their individual cancers can help us as clinicians to tailor
a care plan specifically for them."
Story Source:
The above post is
reprinted from materials provided byUniversity
of Minnesota Academic Health Center. Note: Materials may be edited for content
and length.